Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine
This study has been completed.
Eli Lilly and Company
Information provided by (Responsible Party):
Melissa Delbello, University of Cincinnati
First received: October 27, 2006
Last updated: April 3, 2013
Last verified: April 2013
The primary objective of this study is to examine the efficacy of topiramate in combination with olanzapine for the prevention of weight gain in youth with bipolar disorder. The secondary objective is to examine the tolerability of topiramate in combination with olanzapine for the prevention of weight gain in youth with bipolar disorder.
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
||A Double-Blind, Randomized, Placebo-Controlled, Pilot Study of Topiramate vs. Placebo in Combination With Olanzapine for the Prevention of Weight Gain in Manic or Mixed Youth With Bipolar Disorder
Primary Outcome Measures:
- Change in Body Mass Index (BMI) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
For all participants, BMI was computed using Change in BMI [kg/m2 (weight/height2)] over 12 weeks from Baseline to Week 12.
- Change in Body Weight [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
For all participants, change in body weight in kg over 12 weeks from Baseline to Week 12.
Secondary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||August 2009 (Final data collection date for primary outcome measure)
Experimental: Topiramate Group
Patients' initial dose of topiramate 25mg bid, which was titrated over 18 days to 150 mg bid (with flexibility to titrate to 200mg bid) as tolerated.
Oral topiramate 300-400mg/day for 12 weeks
Other Name: Topamax
Placebo Comparator: Placebo Group
Matched placebo to Experimental arm
Other Name: Sugar pill
After consent and screening, patients will be initiated on 5mg or 10mg per day of olanzapine. Olanzapine doses will be titrated to 10-20 mg of olanzapine over one week, to a maximum of 20mg by day 21. Patients will also receive either topiramate (25mg bid titrated over 18 days to 150 mg bid. with flexibility to titrate to 200mg bid) or matched placebo. Topiramate will be initiated at a dose of 25 mg bid and will be increased by 25 mg bid every three days as tolerated. Patients will be evaluated by a blinded (to treatment status and adverse events) rater.
|Ages Eligible for Study:
||10 Years to 18 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Male or female patients, ages 10-18 years.
- Female patients of menarche must be using a medically accepted means of contraception (e.g. oral contraceptives, Depo-Provera, abstinence).
- Each patient's authorized legal guardian must understand the nature of the study and must provide written informed consent. Each patient must also give assent to study participation.
- Patients must have a diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR) bipolar disorder, type I and currently display an acute manic or mixed episode as determined by K-SADS (Geller et al 2000).
- Patients must have a baseline (day 0) Young Mania Rating Scale score of at least 16.
- Subjects should be fluent in English.
- Female patients who are either pregnant or lactating.
- Clinically significant or unstable hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, hematologic or other systemic medical conditions.
- Any history of current or past diabetes that has been treated with pharmacological intervention.
- Neurological disorders including epilepsy, stroke, or severe head trauma.
- Clinically significant laboratory abnormalities (> 3 times upper limit of normal), on any of the following tests: CBC with differential, electrolytes, BUN, creatinine, hepatic transaminases, lipid profile, fasting glucose, urinalysis, or thyroid indices. Clinically abnormal ECG.
- Manic or mixed episode due to a general medical condition or substance-induced mania (DSM-IV-TR).
- Mental retardation (IQ <70).
- History of hypersensitivity to or intolerance of olanzapine or topiramate.
- Prior history of olanzapine or topiramate non-response or allergic reaction.
- DSM-IV substance (except nicotine or caffeine) dependence within the past 3 months.
- Judged clinically to be at suicidal risk (defined as having active suicidal ideation, intent or plan, or a serious suicide attempt within 30 days, or a baseline Children's Depression Rating Scale suicide score of >3).
- Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections and day 0.
- Treatment with concurrent mood stabilizers or anticonvulsants, benzodiazepines (except as described below), psychostimulants, guanethidine, or guanadrel, or antidepressants.
- Schizophrenia or other psychotic disorders (including schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, psychotic disorder not otherwise specified) as defined in the DSM-IV.
- Major depressive disorder, dysthymic disorder, depressive disorder not otherwise specified.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00394095
|University of Cincinnati Medical Center
|Cincinnati, Ohio, United States, 45267-0559 |
University of Cincinnati
Eli Lilly and Company
||Melissa P DelBello, MD
||University of Cincinnati
No publications provided
||Melissa Delbello, Professor, University of Cincinnati
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 27, 2006
|Results First Received:
||March 23, 2011
||April 3, 2013
||United States: Food and Drug Administration
Keywords provided by University of Cincinnati:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 22, 2014
Affective Disorders, Psychotic
Body Weight Changes
Signs and Symptoms
Central Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Depressants
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents